Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11877265 | 0.91 | SMN1; SMN2 (0.56) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL10040898 | 0.87 | L3MBTL1 (0.69) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL20278587 | 0.87 | GAA (0.67) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL17129733 | 0.87 | L3MBTL1 (0.62) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL9734410 | 0.84 | L3MBTL1 (0.51) | L3MBTL1NPC1MAPTGAAMMP1 | |
| SCHEMBL6640853 | 0.84 | L3MBTL1 (0.60) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL16202982 | 0.84 | L3MBTL1 (0.60) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL17002037 | 0.84 | TP53 (0.70) | L3MBTL1MMP1THRATHRBTP53 | |
| SCHEMBL8172219 | 0.84 | L3MBTL1 (0.74) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL8011974 | 0.84 | MAPT (0.55) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110087729-B | Bifunctional compound with quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-110087729-A | One kind has the dual-function compound of quaternary ammonium salt structure | 北京硕佰医药科技有限责任公司 | 2019-08-02 | — | — | CN | disclosed |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| US-7910605-B2 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2011-03-22 | — | — | US | disclosed |
| EP-2000462-A2 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2008-12-10 | — | — | EP | disclosed |
| US-7169928-B2 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SOCIETE CIVILE BIOPROJECT (FR) | 2007-01-30 | — | — | US | disclosed |
| US-7138413-B1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SOCIETE CIVILE BIOPROJET (FR) | 2006-11-21 | — | — | US | disclosed |
| US-20060247223-A1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SCHWARTZ JEAN-CHARLES | 2006-11-02 | — | — | US | disclosed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | disclosed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1428820-A1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2004-06-16 | — | — | EP | disclosed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247223-A1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | HRH3, HRH4, PNMT | L3MBTL1 825/4885SMN1; SMN2 1979/4885NPC1 1088/4885 |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | L3MBTL1 1621/4885SMN1; SMN2 730/4885NPC1 548/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | L3MBTL1 1955/4885SMN1; SMN2 3925/4885NPC1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.